On Friday, Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) was 0.42% up from the session before settling in for the closing price of $35.51. A 52-week range for RARE has been $29.59 – $60.37.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 48.58%. When this article was written, the company’s average yearly earnings per share was at 19.86%. With a float of $88.41 million, this company’s outstanding shares have now reached $93.74 million.
Considering the fact that the conglomerate employs 1294 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 83.63%, operating margin of -86.94%, and the pretax margin is -92.63%.
Ultragenyx Pharmaceutical Inc (RARE) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Ultragenyx Pharmaceutical Inc stocks. The insider ownership of Ultragenyx Pharmaceutical Inc is 6.49%, while institutional ownership is 95.30%. The most recent insider transaction that took place on May 05 ’25, was worth 20,405. In this transaction EVP and Chief Medical Officer of this company sold 520 shares at a rate of $39.24, taking the stock ownership to the 71,530 shares. Before that another transaction happened on Apr 21 ’25, when Company’s EVP and Chief Medical Officer sold 242 for $35.11, making the entire transaction worth $8,497. This insider now owns 71,680 shares in total.
Ultragenyx Pharmaceutical Inc (RARE) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 19.86% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 83.56% during the next five years compared to 2.45% growth over the previous five years of trading.
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) Trading Performance Indicators
You can see what Ultragenyx Pharmaceutical Inc (RARE) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 2.24. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.71.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.88, a number that is poised to hit -1.28 in the next quarter and is forecasted to reach -3.26 in one year’s time.
Technical Analysis of Ultragenyx Pharmaceutical Inc (RARE)
Compared to the last year’s volume of 0.88 million, its volume of 0.59 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 38.22%. Additionally, its Average True Range was 1.66.
During the past 100 days, Ultragenyx Pharmaceutical Inc’s (RARE) raw stochastic average was set at 35.90%, which indicates a significant decrease from 51.51% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 66.40% in the past 14 days, which was higher than the 47.94% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $36.39, while its 200-day Moving Average is $45.68. Nevertheless, the first resistance level for the watch stands at $35.95 in the near term. At $36.23, the stock is likely to face the second major resistance level. The third major resistance level sits at $36.70. If the price goes on to break the first support level at $35.19, it is likely to go to the next support level at $34.72. Now, if the price goes above the second support level, the third support stands at $34.44.
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) Key Stats
There are 94,542K outstanding shares of the company, which has a market capitalization of 3.37 billion. As of now, sales total 560,230 K while income totals -569,180 K. Its latest quarter income was 139,290 K while its last quarter net income were -151,080 K.
